Evidence map›Paper›PMID 28978804›Full record

ArticleJCI insight2017

Purinergic dysregulation causes hypertensive glaucoma-like optic neuropathy.

Youichi Shinozaki, Kenji Kashiwagi, Kazuhiko Namekata, Akiko Takeda, Nobuhiko Ohno, Bernard Robaye, Takayuki Harada, Takeshi Iwata, Schuichi Koizumi

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. The microglial P2YTranslational neurodegeneration · 2024
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Retina regeneration: lessons from vertebrates.Oxford open neuroscience · 2022
    Review
  8. Review
  9. Role of animal models in glaucoma research.Neural regeneration research · 2020
    Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Youichi ShinozakiDepartment of Neuropharmacology, Interdisciplinary Graduate School of Medicine, and.
Kenji KashiwagiDepartment of Ophthalmology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.
Kazuhiko NamekataVisual Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Akiko TakedaDepartment of Neuropharmacology, Interdisciplinary Graduate School of Medicine, and.
Nobuhiko OhnoDivision of Neurobiology and Bioinformatics, National Institute for Physiological Sciences, Okazaki, Aichi, Japan.
Bernard RobayeInstitute of Interdisciplinary Research and.
Takayuki HaradaVisual Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Takeshi IwataDivision of Molecular and Cellular Biology, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Schuichi KoizumiDepartment of Neuropharmacology, Interdisciplinary Graduate School of Medicine, and.
Tokyo Metropolitan Institute of Medical Science · JPNational Institute for Physiological Sciences · JPTokyo Medical Center · JPUniversité Libre de Bruxelles · BEUniversity of Yamanashi · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glaucoma is an optic neuropathy characterized by progressive degeneration of retinal ganglion cells (RGCs) and visual loss. Although one of the highest risk factors for glaucoma is elevated intraocular pressure (IOP) and reduction in IOP is the only proven treatment, the mechanism of IOP regulation is poorly understood. We report that the P2Y6 receptor is critical for lowering IOP and that ablation of the P2Y6 gene in mice (P2Y6KO) results in hypertensive glaucoma-like optic neuropathy. Topically applied uridine diphosphate, an endogenous selective agonist for the P2Y6 receptor, decreases IOP. The P2Y6 receptor was expressed in nonpigmented epithelial cells of the ciliary body and controlled aqueous humor dynamics. P2Y6KO mice exhibited sustained elevation of IOP, age-dependent damage to the optic nerve, thinning of ganglion cell plus inner plexiform layers, and a reduction of RGC numbers. These changes in P2Y6KO mice were attenuated by an IOP lowering agent. Consistent with RGC damage, visual functions were impaired in middle-aged P2Y6KO mice. We also found that expression and function of P2Y6 receptors in WT mice were significantly reduced by aging, another important risk factor for glaucoma. In summary, our data show that dysfunctional purinergic signaling causes IOP dysregulation, resulting in glaucomatous optic neuropathy.

Indexed as

AgingAnimalsAqueous HumorCiliary BodyDisease Models, AnimalDose-Response Relationship, DrugGlaucomaIntraocular PressureMice, KnockoutOptic Nerve DiseasesReceptors, Purinergic P2Retinal Ganglion CellsSignal TransductionUridine Diphosphatepurinoceptor P2Y6Receptors, Purinergic P2Uridine Diphosphate

Identifiers

PMID28978804
PMCPMC5841869
OpenAlexW2762622877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.